Upload
hoangdung
View
215
Download
0
Embed Size (px)
Citation preview
PowerPoint Presentation
Company Snapshot
NeuroTech Solutions Ltd (NTS) is a leading provider of innovative cloud-based software technologies focused on assessment, monitoring and improvement of human cognition and behavior, with a particular emphasis on attention.
Established Market Presence for ADHD product: MOXO Continuous Performance Test
EU, Americas, Asia, S. Africa
CE approved
National/Regional distributors
Installed Base: 400 centers, 88,000+ tests since launch
>20% sales growth y-y
Additional new markets in process
Dynamic development and clinical research portfolio
2
Karina
2
ADHD Market Drivers
24/7 connectivity, urbanization
Increased awareness, rising social expectations
Shifting diagnostic guidelines
UK Potential Market
According to NICE guidance1, the prevalence of ADHD is 5% of school-aged children. Also according to NICE,
ADHD is currently underdiagnosed in the UK.
1% of school-aged children meet the diagnostic criteria for severe combined type ADHD and should receive treatment (this equates to approximately 100,000 children in the UK). However only 70,000 children are currently receiving medication for their ADHD.
Over half (54%) of the child and adolescent psychiatrists and community pediatricians recently surveyed also stated that ADHD is currently underdiagnosed in the UK
1 National Institute for Clinical Excellence. Technology Appraisal Guidance No. 13. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention-Deficit/Hyperactivity Disorder (ADHD) in childhood. October 2000
3
UK Survey Findings3: the potential impact of undiagnosed and untreated ADHD
ADHD was rated as having as great an impact on a childs development as depression, Tourettes Syndrome, anxiety or dyslexia. 80% of specialists surveyed rated ADHD as having the greatest or second greatest impact of these conditions on a childs development
98% of those surveyed believed undiagnosed ADHD has a serious impact on a childs academic progress and they are more likely to drop out of school several years earlier than their peers
Over 90% said that undiagnosed and untreated ADHD:
Has a serious impact on a childs relationships with their parents, siblings and peers
Can result in children feeling excluded from their peers, impacting their ability to make friends and leading to very low self-esteem due to their exclusion
Can lead to a variety of social problems, such as difficulties finding and keeping a job and criminal behavior (such as stealing, shoplifting and vandalism)
4
3 Synergy Healthcare Research: ADHD in the UK Today. Survey of 50 child and adolescent psychiatrists and 75 paediatricians, July 2003
4
5
ADHD Assessment Tools
DSM-IV or ICD-10
Questionnaires completed by the specialist, parents and teachers e.g. Conners Teacher and Parent
Rating Scales
Tests which measure the length and type of mental process (psychometric tests and profiles)
Tests of attention and persistence e.g. Continuous Performance Test (CPT)
Challenging diagnostic environment:
ADHD symptoms overlap with those of other disorders
6
Other psychiatric/behavioral disorder
Stimulant Addiction/Enhancement
ADHD with Comorbidity
Pure Attention Disorder
Diagnosis of ADHD can be difficult because other problems (such as autism, Aspergers Syndrome, epilepsy, depression, brain injury or family dysfunction) can result in behavior similar to ADHD.
Perception of over diagnosis and overprescribing
CD, ODD
6
7
Unmet need:
easily-deployed, cost-effective, objective tool
to support clinical diagnosis and research
Next Generation Solution: MOXO d-CPT Test
Accessible
8
Expensive
Limited
Affordable
NEBA
Quotient
AULA
IVA+
QBtest
Conners CPT III
GDS
T.O.V.A
9
MOXO:
Streamlined,
Effective Assessment of Attention
Low Overhead
Patient-Centric
Objective
Innovative
Universal
Secure
Cloud-based, no specialized HW
Accessible from anywhere
Automated, immediate results
Contemporary reference group collected across four continents
Novel multimodal distractor- approach simulates real-life, sensory and emotional features
No language/number confounds
Pediatric and teen/adult versions
HIPAA and EU privacy compliant
10
Demonstration of MOXO Stimuli
Pediatric Version
Click on graphic to view demonstration
Demonstration of MOXO Stimuli
Teens/Adults Version
Karina
Not pediatric version with age-appropriate stimuli/distractors
11
Test Results Reports
Patient Profile
Comparison of individual performance to norm group.
Norm criteria: age and gender
Indices: Attention, Timing, Hyperactivity and Impulsiveness
Scoring: Calculated for each index and categorized by performance level
Includes severity measure for aberrant scores
Performance Graph
Maps performance throughout the test
Baseline
Major/Minor auditory
Major/Minor visual
Combined
Provides distractor impact by index
Example: impulsivity change due to major visual distractors
13
Market Segments
Additional Verticals:
Universities, HR agencies, Driver ExaminationCenters,
A diagnosis of ADHD should only be made by a specialist psychiatrist, pediatrician or other appropriately qualified healthcare professional with training and expertise in the diagnosis of ADHD (NICE Guidelines)
Patient: Female | 14Y
Use Case: NeurologistPharmacotherapy Assessment & Monitoring
Unmedicated
MPH 10 mg
MPH 36 mg
MPH 54 mg
Clinician tracked patient status titration process for selection of optimal drug dose
14
Use Case: Psychologist
Monitoring Utility of Psychotherapy
Before
After
Female | 14y
Psychologist tracked patient status across therapy sessions to assess effectiveness of approach
j
15
16
MOXO: Supporting Eco-System
MOXO
School system
Health System
Professi-onals
Key Scientific Advisors
Edmund Sonuga-Barke, PhD
Member, World Health Org. workgroup on Future of Psychiatric Diagnosis
Itai Berger, MD
Director, Pediatric Neurology Unit and Neuro-Cognitive Center, Hadassah University Hospital
David Coghill, MD
Reader in Child and Adolescent Psychiatry, University of Dundee, UK Visiting Professor of Child and Adolescent Psychiatry, Ning-Bo University, China
MOXO: business opportunity
18
Need: Growing demand for ADHD diagnosis
The MOXO Solution: objective, accurate, based on modern norms
Significant market presence: Turkey, Poland, S. Africa, Mexico, Spain, Israel and additional markets underway
Market acceptance: consistently used by hospitals, universities, large clinics around the globe
ROI: low overhead, streamlined cloud-base service
Clinician-centric tools: coherent results report, developmental report, comparative report (for longitude monitoring), large data base analytics, GCP compliant clinical system
www.neurotech-solutions.com I www.moxo-adhdtest.com